FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136261618> ?p ?o ?g. }

• W3136261618 endingPage "680" @default.
• W3136261618 startingPage "676" @default.
• W3136261618 abstract "Recently, Vigil showed significant clinical benefit with improvement in relapse free (RFS) and overall survival (OS) in pre-planned subgroup analysis in stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) molecular profile. Here we analyze homologous recombination (HR) status of patients enrolled in the Phase 2b VITAL study and determine clinical benefit of Vigil in HR proficient (P) patients.Patients were previously enrolled in a Phase 2b, double-blind, placebo-controlled trial. All were in complete response with Stage III/IV high grade serious, endometroid or clear cell ovarian cancer. HR status was determined using MyChoice®CDx score (<42 = HRP) (Myriad Genetics, Inc., UT). Post-hoc analyses were carried out using Kaplan Meier and restricted mean survival time (RMST) analysis to evaluate RFS and OS based on HR deficiency (D) status.RFS was improved with Vigil (n = 25) in HRP patients compared to placebo (n = 20) (HR = 0.386; 90% CI 0.199-0.750; p = 0.007), results were verified by RMST (p = 0.017). Similarly, OS benefit was observed in Vigil group compared to placebo (HR = 0.342; 90% CI 0.141-0.832; p = 0.019). Results with OS were also verified with RMST (p = 0.008).Vigil exhibited clinical benefit in HRP molecular profile patients." @default.
• W3136261618 created "2021-03-29" @default.
• W3136261618 creator A5006242906 @default.
• W3136261618 creator A5008763534 @default.
• W3136261618 creator A5009234043 @default.
• W3136261618 creator A5014611244 @default.
• W3136261618 creator A5017494786 @default.
• W3136261618 creator A5032051379 @default.
• W3136261618 creator A5042371948 @default.
• W3136261618 creator A5046995957 @default.
• W3136261618 creator A5052040011 @default.
• W3136261618 creator A5055054082 @default.
• W3136261618 creator A5064537232 @default.
• W3136261618 creator A5071282536 @default.
• W3136261618 creator A5073062815 @default.
• W3136261618 date "2021-06-01" @default.
• W3136261618 modified "2023-10-02" @default.
• W3136261618 title "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" @default.
• W3136261618 cites W1987657194 @default.
• W3136261618 cites W2291298003 @default.
• W3136261618 cites W2521102102 @default.
• W3136261618 cites W2523859159 @default.
• W3136261618 cites W2897430921 @default.
• W3136261618 cites W2951714360 @default.
• W3136261618 cites W2975141952 @default.
• W3136261618 cites W2991893034 @default.
• W3136261618 cites W2994977341 @default.
• W3136261618 cites W3080364487 @default.
• W3136261618 cites W3087434055 @default.
• W3136261618 cites W3108804421 @default.
• W3136261618 cites W4251361525 @default.
• W3136261618 doi "https://doi.org/10.1016/j.ygyno.2021.03.009" @default.
• W3136261618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33715892" @default.
• W3136261618 hasPublicationYear "2021" @default.
• W3136261618 type Work @default.
• W3136261618 sameAs 3136261618 @default.
• W3136261618 citedByCount "20" @default.
• W3136261618 countsByYear W31362616182021 @default.
• W3136261618 countsByYear W31362616182022 @default.
• W3136261618 countsByYear W31362616182023 @default.
• W3136261618 crossrefType "journal-article" @default.
• W3136261618 hasAuthorship W3136261618A5006242906 @default.
• W3136261618 hasAuthorship W3136261618A5008763534 @default.
• W3136261618 hasAuthorship W3136261618A5009234043 @default.
• W3136261618 hasAuthorship W3136261618A5014611244 @default.
• W3136261618 hasAuthorship W3136261618A5017494786 @default.
• W3136261618 hasAuthorship W3136261618A5032051379 @default.
• W3136261618 hasAuthorship W3136261618A5042371948 @default.
• W3136261618 hasAuthorship W3136261618A5046995957 @default.
• W3136261618 hasAuthorship W3136261618A5052040011 @default.
• W3136261618 hasAuthorship W3136261618A5055054082 @default.
• W3136261618 hasAuthorship W3136261618A5064537232 @default.
• W3136261618 hasAuthorship W3136261618A5071282536 @default.
• W3136261618 hasAuthorship W3136261618A5073062815 @default.
• W3136261618 hasConcept C121608353 @default.
• W3136261618 hasConcept C126322002 @default.
• W3136261618 hasConcept C141071460 @default.
• W3136261618 hasConcept C142724271 @default.
• W3136261618 hasConcept C143998085 @default.
• W3136261618 hasConcept C166957645 @default.
• W3136261618 hasConcept C204787440 @default.
• W3136261618 hasConcept C27081682 @default.
• W3136261618 hasConcept C2778447413 @default.
• W3136261618 hasConcept C2780427987 @default.
• W3136261618 hasConcept C535046627 @default.
• W3136261618 hasConcept C67761136 @default.
• W3136261618 hasConcept C71924100 @default.
• W3136261618 hasConcept C90924648 @default.
• W3136261618 hasConcept C95457728 @default.
• W3136261618 hasConceptScore W3136261618C121608353 @default.
• W3136261618 hasConceptScore W3136261618C126322002 @default.
• W3136261618 hasConceptScore W3136261618C141071460 @default.
• W3136261618 hasConceptScore W3136261618C142724271 @default.
• W3136261618 hasConceptScore W3136261618C143998085 @default.
• W3136261618 hasConceptScore W3136261618C166957645 @default.
• W3136261618 hasConceptScore W3136261618C204787440 @default.
• W3136261618 hasConceptScore W3136261618C27081682 @default.
• W3136261618 hasConceptScore W3136261618C2778447413 @default.
• W3136261618 hasConceptScore W3136261618C2780427987 @default.
• W3136261618 hasConceptScore W3136261618C535046627 @default.
• W3136261618 hasConceptScore W3136261618C67761136 @default.
• W3136261618 hasConceptScore W3136261618C71924100 @default.
• W3136261618 hasConceptScore W3136261618C90924648 @default.
• W3136261618 hasConceptScore W3136261618C95457728 @default.
• W3136261618 hasFunder F4320307115 @default.
• W3136261618 hasFunder F4320322783 @default.
• W3136261618 hasFunder F4320332193 @default.
• W3136261618 hasIssue "3" @default.
• W3136261618 hasLocation W31362616181 @default.
• W3136261618 hasLocation W31362616182 @default.
• W3136261618 hasOpenAccess W3136261618 @default.
• W3136261618 hasPrimaryLocation W31362616181 @default.
• W3136261618 hasRelatedWork W1586374228 @default.
• W3136261618 hasRelatedWork W2003938723 @default.
• W3136261618 hasRelatedWork W2047967234 @default.
• W3136261618 hasRelatedWork W2089201504 @default.
• W3136261618 hasRelatedWork W2118496982 @default.
• W3136261618 hasRelatedWork W2364998975 @default.

• next